CARLSBAD, Calif., May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE) demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of >90% with one year of treatment for both monthly or every two-month dosing. Patients who switched to donidalorsen from prior prophylactic treatment also sh ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

In a shortened week of trading following the Memorial Day weekend, investors may want to take notice of several medical stocks that were added to the Zacks Rank #1 (Strong Buy) list today. Standing out in terms of valuation with earnings estimates on the rise as well, here are three of these highly ranked medical stocks to consider. Haemonetics (HAE) More intriguing is that Lantheus' P/E valuation of 11X looks cheap especially considering FY24 earnings estimates have spiked 8% over the last 30 days while FY ...

Group 1 - MINISO Group Holding Limited (MNSO) has a Zacks Rank 1 with a 12.5% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - MINISO's shares increased by 22.8% over the last three months, outperforming the S&P 500's 1.1% gain [1] - MINISO possesses a Momentum Score of A [1] Group 2 - Lightspeed Commerce Inc. (LSPD) has a Zacks Rank 1 with a 46.7% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [2] - Lightspeed's shares gained 7.9% over the last three months, also outperforming the S&P 500's 1.1% gain [2] - Lightspeed possesses a Momentum Score of A [2] Group 3 - Haemonetics Corporation (HAE) has a Zacks Rank 1 with a 7.6% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [3] - Haemonetics' shares increased by 21% over the last three months, significantly outperforming the S&P 500's 1.1% gain [3] - Haemonetics possesses a Momentum Score of B [3]

In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Haemonetics (HAE) is on the list of such stocks currently recommended b ...

Core Viewpoint - The article compares Haemonetics (HAE) and Boston Scientific (BSX) to determine which stock offers better value for investors at the current time [1]. Valuation Metrics - HAE has a forward P/E ratio of 19.42, while BSX has a forward P/E of 32.58 [5]. - HAE's PEG ratio is 1.62, indicating a more favorable valuation compared to BSX's PEG ratio of 2.60 [5]. - HAE's P/B ratio stands at 4.67, compared to BSX's P/B of 5.51 [6]. - Based on these valuation metrics, HAE is assigned a Value grade of B, while BSX receives a Value grade of C [6]. Earnings Outlook - Both HAE and BSX currently hold a Zacks Rank of 2 (Buy), indicating an improving earnings outlook due to positive analyst estimate revisions [3]. - The Zacks Rank strategy targets companies with favorable earnings estimate trends, which applies to both HAE and BSX [2]. Investment Recommendation - Based on the analysis of valuation figures and earnings outlook, HAE is considered the superior value option compared to BSX at this time [6].

Haemonetics (HAE) closed the last trading session at $88.64, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.20 indicates a 26.6% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $12.15. While the lowest estimate of $94 indicates a 6.1% increase from the current price level, the most optimistic analyst expect ...

Core Viewpoint - Haemonetics (HAE) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Haemonetics for the fiscal year ending March 2025 is projected at $4.46 per share, reflecting a 12.6% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Haemonetics has risen by 9.8%, indicating a trend of increasing earnings estimates [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 1 places Haemonetics in the top 5% of Zacks-covered stocks, suggesting a strong potential for stock price appreciation in the near term [11]. Market Dynamics - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [4]. - The Zacks rating system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks are considered for strong recommendations, which enhances the likelihood of market-beating returns [9].

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amo ...

Core Viewpoint - Haemonetics is positioned for growth due to the strong potential of its Plasma franchise and evolving hospital portfolio, despite facing economic uncertainties and foreign exchange challenges [1][11]. Financial Performance - The stock has increased by 11.7% over the past year, outperforming the industry, which fell by 1.3%, and the S&P 500, which rose by 26.7% [2]. - Haemonetics has a market capitalization of $4.84 billion and has consistently surpassed earnings estimates, achieving an average earnings surprise of 13.24% over the last four quarters [2]. Business Segments Plasma Franchise - The Plasma business unit focuses on collecting source plasma, with revenues growing by 6% in Q4 of fiscal 2024, driven by disposable volume and software [3]. - The collections environment in the U.S. remains favorable, with disposables growing by 4% in the quarter and 13% for fiscal 2024 [3]. - The rollout of the Express Plus technology has resulted in over 60,000 real-world collections, enhancing operational efficiency [3][4]. Hospital Business - Hospital revenues increased by 19% in Q4, supported by the success of Vascular Closure and hemostasis management [5]. - The Vascular Closure business is expanding due to new account openings in electrophysiology and interventional cardiology [5]. - The FDA's premarket approval for the VASSCADE MVPXL device and the ongoing international launch contributed approximately 300 basis points to revenue growth in Q4 [6]. Acquisitions and Innovations - In December 2023, Haemonetics acquired OpSens, enhancing its Hospital business with new technologies, generating nearly $10 million in revenues in Q4 [7]. - The launch of OptiWire and SavvyWire in April further supports the company's growth strategy [7]. Financial Stability - Haemonetics ended Q4 with cash and cash equivalents of $178.8 million and near-term payable debt of $10.2 million, indicating strong solvency [8]. - Long-term debt decreased to $797.6 million from $856.8 million in the previous quarter, with a total debt-to-capital ratio of 45.7%, down from 47.6% [10]. Challenges - Economic uncertainties, including inflation and rising interest rates, pose risks to Haemonetics' operations, leading to 700 basis points of margin pressure in Q4 [11]. - Foreign exchange fluctuations, particularly with the Japanese Yen and Euro, negatively impacted revenues due to international sales being conducted in local currencies [12]. Future Estimates - The Zacks Consensus Estimate for Haemonetics' fiscal 2025 earnings has increased to $4.46 from $4.24, with revenues projected at $1.40 billion, reflecting a 6.9% increase from the previous year [13].